| | | | | 1 | | | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | | | 6 | | | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | | | 13 | | | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | |
|
| | ||
| | | | | 17 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 41 | | | |
| | | | | 42 | | | |
| | | | | 43 | | | |
| | | | | 44 | | | |
| | | | | 49 | | | |
| | | | | 50 | | | |
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| | ||
| | | |
|
| |
Name of Director Nominee
|
| |
Age
|
| |
Title
|
| |
Director Since
|
|
Lindsay A. Rosenwald, M.D.
|
| |
63
|
| | Chairman, President and Chief Executive Officer | | | October 2009 | |
Eric K. Rowinsky, M.D. | | |
61
|
| | Co-Vice Chairman and Director | | | October 2010 | |
Jimmie Harvey, Jr., M.D. | | |
66
|
| | Director | | | December 2008 | |
Malcolm Hoenlein | | |
74
|
| | Director | | | February 2014 | |
Dov Klein | | |
66
|
| | Director | | | July 2015 | |
J. Jay Lobell | | |
55
|
| | Director | | | June 2006 | |
Michael S. Weiss | | |
52
|
| | Director and Executive Vice Chairman, Strategic Development | | | December 2013 | |
Name
|
| |
Age
|
| |
Position
|
|
Lindsay A. Rosenwald, M.D. | | |
63
|
| | Executive Chairman, Chief Executive Officer and President | |
Robyn M. Hunter | | |
56
|
| | Chief Financial Officer, Treasurer and Corporate Secretary | |
Michael S. Weiss | | |
52
|
| | Executive Vice Chairman, Strategic Development | |
George Avgerinos, Ph.D. | | |
65
|
| | Senior Vice President, Biologics Operations | |
Name and principal position(s)
|
| |
Year
|
| |
Salary
(1)
($) |
| |
Bonus
(2)
($) |
| |
Stock
Awards (3) ($) |
| |
Non-equity
Incentive Plan Compensation (4) ($) |
| |
All Other
Compensation (5) ($) |
| |
Total
($) |
| |||||||||||||||||||||
Lindsay A. Rosenwald, M.D.
(6)
Chairman, President and Chief Executive Officer |
| | | | 2017 | | | | | $ | 30,579 | | | | | $ | — | | | | | $ | 1,539,285 | | | | | $ | 500,000 | | | | | $ | 125 | | | | | $ | 2,069,989 | | |
| | | 2016 | | | | | | 29,689 | | | | | | — | | | | | | 1,504,285 | | | | | | 500,000 | | | | | | 20 | | | | | | 2,033,994 | | | ||
| | | 2015 | | | | | | 28,275 | | | | | | — | | | | | | 2,538,452 | | | | | | 500,000 | | | | | | — | | | | | | 3,066,727 | | | ||
Robyn M. Hunter
Chief Financial Officer and Corporate Secretary |
| | | | 2017 | | | | | | 293,347 | | | | | | 117,339 | | | | | | 1,115,000 | | | | | | — | | | | | | 820 | | | | | | 1,526,506 | | |
Lucy Lu, M.D.
Former Chief Financial Officer |
| | | | 2017 | | | | | | 174,879 | | | | | | — | | | | | | — | | | | | | — | | | | | | 410 | | | | | | 175,288 | | |
| | | 2016 | | | | | | 339,570 | | | | | | 135,828 | | | | | | — | | | | | | — | | | | | | 820 | | | | | | 476,218 | | | ||
| | | 2015 | | | | | | 323,400 | | | | | | 129,360 | | | | | | — | | | | | | — | | | | | | 820 | | | | | | 453,580 | | | ||
George Avgerinos, Ph.D.
Senior Vice President, Biologics Operation |
| | | | 2017 | | | | | | 374,740 | | | | | | 299,792 | | | | | | — | | | | | | — | | | | | | — | | | | | | 674,532 | | |
| | | 2016 | | | | | | 363,825 | | | | | | 145,530 | | | | | | — | | | | | | — | | | | | | — | | | | | | 509,355 | | | ||
| | | 2015 | | | | | | 346,500 | | | | | | 138,600 | | | | | | 3,710,000 | | | | | | — | | | | | | — | | | | | | 4,195,100 | | | ||
Michael S. Weiss
(6)
Executive Vice Chairman, Strategic Development |
| | | | 2017 | | | | | | 30,579 | | | | | | — | | | | | | 1,539,285 | | | | | | 500,000 | | | | | | 120 | | | | | | 2,069,989 | | |
| | | 2016 | | | | | | 29,689 | | | | | | — | | | | | | 1,504,285 | | | | | | 500,000 | | | | | | 15 | | | | | | 2,153,989 | | | ||
| | | 2015 | | | | | | 28,275 | | | | | | — | | | | | | 2,538,452 | | | | | | 500,000 | | | | | | — | | | | | | 3,066,727 | | |
Name
|
| |
Grant Date
|
| |
Estimated
Possible Payouts under Non-Equity Incentive Plan Awards ($) |
| |
All
Other Stock Awards: Number of Shares of Stock (#) |
| |
All
Other Awards: Number of Securities Underlying Options (#) |
| |
Exercise
or Base Price of Option Awards ($/Sh) |
| |
Grant Date
Fair Value of Stock and Option Awards (1) ($) |
| |||||||||||||||
Robyn M. Hunter
|
| | | | 09/18/2017 (1 ) | | | | | | | | | | | | | | | | | | 250,000 | | | | | | | | $ | 1,115,000 | | |
Lindsay A. Rosenwald, M.D.
|
| | | | 01/01/2017 (2 ) | | | | | | | | | | | | 552,698 | | | | | | | | | | | | | | $ | 1,492,285 | | |
| | | | | 6/21/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 14,000 | | |
| | | | | 7/28/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 10,000 | | |
| | | | | 9/30/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 2,000 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | | | | | | $ | 500,000 (4) | | | | | | | |||||||||||||||||
Michael S. Weiss
|
| | | | 01/01/2017 (2 ) | | | | | | | | | | | | 552,698 | | | | | | | | | | | | | | $ | 1,492,285 | | |
| | | | | 6/21/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 14,000 | | |
| | | | | 7/28/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 10,000 | | |
| | | | | 9/30/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 2,000 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | 12/31/2017 (3 ) | | | | | | | | | | | | 500,000 | | | | | | | | | | | | | | | 3,500 | | |
| | | | | | | | | | $ | 500,000 (4) | | | | | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares of Units of Stock That Have Not Vested (#) |
| |
Market Value of
Shares or Units of Stock That Have Not Vested ($) (1) |
| |
Equity
Incentive Plan Awards: Number or Unearned Shares (#) |
| |
Equity Incentive
Plan Awards: Market or Payout Value of Unearned Shares ($) |
| ||||||||||||||||||||||||
Lindsay A. Rosenwald, M.D.
(7)
|
| | | | 25,000 | | | | | | — | | | | | $ | 1.37 | | | | | | 10/05/2020 | | | | | | 1,063,132 | | | | | | 4,241,897 | | | | | | 1,979,346 (2) | | | | | $ | 7,897,591 | | |
| | | | | 15,000 | | | | | | — | | | | | | 6.250 | | | | | | 02/10/2022 | | | | | | | ||||||||||||||||||||
| | | | | 15,000 | | | | | | — | | | | | | 7.420 | | | | | | 02/07/2023 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.150 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.130 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 1.190 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.070 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.100 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.650 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.150 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.024 | | | | | | 10/31/2026 | | | | | | | ||||||||||||||||||||
Lucy Lu, M.D.
|
| | | | 225,000 | | | | | | — | | | | | | 6.850 | | | | | | 02/22/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
George Avgerinos, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 400,000 (3) | | | | | | 1,596,000 | | |
Michael
S. Weiss (7) |
| | | | 30,000 | | | | | | — | | | | | | 2.100 | | | | | | 12/19/2023 | | | | | | 1,063,132 | | | | | | 4,241,897 | | | | | | 1,979,346 (4) | | | | | | 7,897,591 | | |
| | | | | 500,000 | | | | | | — | | | | | | 0.150 | | | | | | 07/15/2025 | | | | | | 3,298,778 (5) | | | | | | 13,162,651 | | | | | | — | | | | | | — | | |
| | | | | 500,000 | | | | | | — | | | | | | 0.130 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 1.190 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.070 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.100 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.650 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.150 | | | | | | 07/15/2025 | | | | | | | ||||||||||||||||||||
| | | | | 500,000 | | | | | | — | | | | | | 0.024 | | | | | | 10/31/2026 | | | | | | | ||||||||||||||||||||
Robyn M. Hunter
|
| | | | 30,000 | | | | | | — | | | | | | 2.950 | | | | | | 08/17/2021 | | | | | | — | | | | | | — | | | | | | 250,000 | | | | | | 997,500 | | |
| | | | | 30,000 | | | | | | — | | | | | | 5.720 | | | | | | 08/16/2022 | | | | | | | | | | | |
Name
|
| |
Number of
Shares Acquired on Vesting (#) |
| |
Value
Realized on Vesting ($) (1) |
||||||
Lindsay A. Rosenwald, M.D. (3) | | | | |||||||||
Aevitas
|
| | | | 500,000 | | | | | $ | 10,000 | |
Cyprium
|
| | | | 500,000 | | | | | | 2,000 | |
Caelum Bio. Inc.
|
| | | | 500,000 | | | | | | 14,000 | |
FBIO Acquisition Corp. III
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. IV
|
| | | | 500,000 | | | | | | 3,500 | |
Tamid Bio Inc. (formerly FBIO Acquisition Corp. V)
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VI
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VII
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VIII
|
| | | | 500,000 | | | | | | 3,500 | |
Michael S. Weiss (3) | | | | |||||||||
Aevitas
|
| | | | 500,000 | | | | | $ | 10,000 | |
Cyprium
|
| | | | 500,000 | | | | | | 2,000 | |
Caelum Bio. Inc.
|
| | | | 500,000 | | | | | | 14,000 | |
FBIO Acquisition Corp. III
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. IV
|
| | | | 500,000 | | | | | | 3,500 | |
Tamid Bio Inc. (formerly FBIO Acquisition Corp. V)
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VI
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VII
|
| | | | 500,000 | | | | | | 3,500 | |
FBIO Acquisition Corp. VIII
|
| | | | 500,000 | | | | | | 3,500 | |
George Avgerinos, M.D.
|
| | | | 150,000 (2) | | | | | $ | 600,000 |
| | |
Upon Termination without Cause
or Resignation for Good Reason – No Change of Control |
| |
Upon Termination without Cause or
Resignation for Good Reason – Change of Control |
| ||||||||||||||||||||||||||||||
Name
|
| |
Cash
Severance |
| |
Value of
Accelerated Vesting (1) |
| |
Total
|
| |
Cash
Severance |
| |
Value of
Accelerated Vesting (1) |
| |
Total
|
| ||||||||||||||||||
Lindsay A. Rosenwald, M.D.
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 12,139,487 | | | | | $ | 12,139,487 | | |
Robyn M. Hunter
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
George Avgerinos, Ph.D.
|
| | | $ | 374,740 | | | | | $ | 598,500 | | | | | $ | 1,272,512 | | | | | $ | 374,740 | | | | | $ | 1,596,000 | | | | | $ | 2,270,012 | | |
Michael S. Weiss
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 25,302,138 | | | | | $ | 25,302,138 | | |
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units, Warrants and Rights (a) |
| |
Weighted-Average
Exercise Price of Outstanding Options, Warrants and Rights (b) |
| |
Number of
Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c) |
| |||||||||
Equity compensation plans approved by stockholders
|
| | | | 4,921,751 | | | | | $ | 3.95 | | | | | | 3,493,321 | | |
Equity compensation plans not approved by stockholders
|
| | | | — | | | | | $ | — | | | | | | — | | |
Total
|
| | | | 4,921,751 | | | | | | | | | | | | 3,493,321 | | |
|
Name
|
| |
Fees Earned
or paid in Cash (1) ($) |
| |
Stock
Awards (2) ($) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Jimmie Harvey, Jr., M.D.
|
| | | $ | 47,500 | | | | | $ | 270,000 (3) | | | | | $ | — | | | | | $ | 326,500 | | |
Malcolm Hoenlein
|
| | | | 35,000 | | | | | | 135,000 (3) | | | | | | — | | | | | | 174,000 | | |
Dov Klein
|
| | | | 60,000 | | | | | | 270,000 (4) | | | | | | — | | | | | | 339,000 | | |
J. Jay Lobell
|
| | | | 67,500 | | | | | | 270,000 | | | | | | — | | | | | | 326,000 | | |
Eric K. Rowinsky, M.D.
|
| | | | 35,000 | | | | | | 270,000 | | | | | | 250,000 (5) | | | | | | 564,000 | | |
Fortress Company
|
| |
Effective Date
(1)
|
| |
PIK Dividend as
a % of fully diluted outstanding capitalization |
| |
Class of
Stock Issued |
| |||
Helocyte
|
| | March 20, 2015 | | | | | 2.5 % | | | |
Common Stock
|
|
Avenue
|
| | February 17, 2015 | | | | | 2.5 % | | | |
Common Stock
|
|
Mustang
|
| | March 13, 2015 | | | | | 2.5 % | | | |
Common Stock
|
|
Checkpoint
|
| | March 17, 2015 | | | | | 0.0 % (2) | | | |
Common Stock
|
|
Cellvation
|
| | October 31, 2016 | | | | | 2.5 % | | | |
Common Stock
|
|
Caelum
|
| | January 1, 2017 | | | | | 2.5 % | | | |
Common Stock
|
|
Cyprium
|
| | March 13, 2017 | | | | | 2.5 % | | | |
Common Stock
|
|
Aevitas
|
| | July 28, 2017 | | | | | 2.5 % | | | |
Common Stock
|
|
Tamid
|
| |
November 30, 2017
(3)
|
| | | | 2.5 % | | | |
Common Stock
|
|
Fortress Company
|
| |
PIK Dividend
Date |
| |
Year Ended
December 31, 2017 1 |
| |
Year Ended
December 31, 2016 |
| ||||||
Aevitas 2 | | | July 28 | | | | $ | — | | | | | $ | — | | |
Avenue
|
| | February 17 | | | | | 1,103 | | | | | | 49 | | |
Caelum
|
| | January 1 | | | | | 302 | | | | | | — | | |
Cellvation
|
| | October 31 | | | | | 8 | | | | | | — | | |
Checkpoint
|
| | March 17 | | | | | 2,296 | | | | | | 3,919 | | |
Cyprium
|
| | January 1 | | | | | 1 | | | | | | — | | |
Helocyte
|
| | March 20 | | | | | 321 | | | | | | — | | |
Mustang
|
| | March 13 | | | | | 9,479 | | | | | | 4,396 | | |
Tamid 3 | | | November 30 | | | | | — | | | | | | — | | |
Fortress
|
| | | | | | | (13,510 ) | | | | | | (8,364 ) | | |
Consolidated (Income)/Expense
|
| | | | | | $ | — | | | | | $ | — | | |
|
Fortress Company
|
| |
Effective Date
|
| |
R&D
|
| |
G&A
|
| |
Annual MSA Fee
(Income)/Expense |
| |||||||||
Helocyte
|
| | March 20, 2015 | | | | $ | 250 | | | | | $ | 250 | | | | | $ | 500 | | |
Avenue
|
| | February 17, 2015 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Mustang
|
| | March 13, 2015 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Checkpoint
|
| | March 17, 2015 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Cellvation
|
| | October 31, 2016 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Caelum
|
| | January 1, 2017 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Cyprium
|
| | March 13, 2017 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Aevitas
|
| | July 28, 2017 | | | | | 250 | | | | | | 250 | | | | | | 500 | | |
Tamid
|
| |
November 30, 2017
(1)
|
| | | | 250 | | | | | | 250 | | | | | | 500 | | |
Fortress
|
| | | | | | | (2,250 ) | | | | | | (2,250 ) | | | | | | (4,500 ) | | |
Consolidated (Income)/Expense
|
| | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
|
Fortress Company
|
| |
Description
|
| |
September 30,
2017 |
| |
September 30,
2016 |
| ||||||
Fortress
|
| | Subordinated Financing | | | | $ | 2,836 | | | | | $ | — | | |
Avenue
|
| | IPO Fees | | | | | 2,331 | | | | | | — | | |
Mustang
|
| | Private Placement Offering | | | | | 9,527 | | | | | | 1,265 | | |
Caelum
|
| | Convertible Debt Raise | | | | | 991 | | | | | | — | | |
Total Fees per Fortress
|
| | | | | | | 15,685 | | | | | | 1,265 | | |
Less:
|
| |
Mustang fee recorded by National in 2016
|
| | | | 1,265 | | | | | | — | | |
Total National Fees
|
| | | | | | $ | 14,420 | | | | | $ | 1,265 | | |
|
Name and Address of Beneficial Owner
|
| |
Shares Owned
|
| |
Shares Under
Exercisable Options and Unvested Restricted Stock Units (1) |
| |
Total Shares
Beneficially Owned |
| |
Percentage
Beneficially Owned |
| ||||||||||||
5% or Greater Stockholder: | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors and Named Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | |
Michael S. Weiss
|
| | | | 8,587,598 | | | | | | 30,000 | | | | | | 8,617,598 | | | | | | 16.4 % | | |
Lindsay A. Rosenwald, M.D.
|
| | | | 7,358,172 (2) | | | | | | 55,000 | | | | | | 7,413,172 | | | | | | 14.1 % | | |
J. Jay Lobell
|
| | | | 786,000 | | | | | | 85,000 | | | | | | 871,000 | | | | | | 1.7 % | | |
Eric K. Rowinsky, M.D.
|
| | | | 450,000 | | | | | | 238,490 | | | | | | 688,490 | | | | | | 1.3 % | | |
George C. Avgerinos, Ph.D.
|
| | | | 352,495 | | | | | | — | | | | | | 352,495 | | | | | | * % | | |
Robyn M. Hunter
|
| | | | 10,129 | | | | | | 60,000 | | | | | | 70,129 | | | | | | * % | | |
Jimmie Harvey, Jr., M.D.
|
| | | | 50,000 | | | | | | 85,000 | | | | | | 135,000 | | | | | | * % | | |
Dov Klein
|
| | | | 76,800 (3) | | | | | | — | | | | | | 76,800 | | | | | | * % | | |
Malcolm Hoenlein
|
| | | | 55,000 | | | | | | — | | | | | | 55,000 | | | | | | * % | | |
All current executive officers and directors as a group (9 persons)
|
| | | | 17,726,194 | | | | | | 553,490 | | | | | | 18,279,684 | | | | | | 34.7 % | | |
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units, Warrants and Rights (a) |
| |
Weighted-Average
Exercise Price of Outstanding Options, Warrants and Rights (b) |
| |
Number of
Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) (c) |
| |||||||||
Equity compensation plans approved by stockholders
|
| | | | 4,921,751 | | | | | $ | 3.95 | | | | | | 3,493,321 | | |
Equity compensation plans not approved by stockholders
|
| | | | — | | | | | $ | — | | | | | | — | | |
Total
|
| | | | 4,921,751 | | | | | | | | | | | | 3,493,321 | | |
|